We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid PCR Testing in ICU Improves Antibiotic Stewardship

By LabMedica International staff writers
Posted on 07 Mar 2025

A collaborative study led by the University of Plymouth (Devon, UK) has shown that rapid polymerase chain reaction (PCR) testing in the intensive care unit (ICU) improved antibiotic stewardship compared to standard care, although it did not demonstrate non-inferiority in the clinical cure of pneumonia. More...

The INHALE WP3 trial, a multicenter, open-label, pragmatic randomized controlled trial, evaluated the impact of rapid, ICU-based syndromic PCR testing versus standard culture-based microbiological testing on antibiotic stewardship and clinical outcomes in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in the UK. The study involved 453 adults (median age, 61 years) and 92 children (median age, 7.5 months) with HAP or VAP, who were either about to begin empiric antibiotic treatment or have their current therapy modified. Participants were randomly assigned to receive either rapid syndromic PCR testing in the ICU or standard microbiological testing. The primary outcomes assessed were: superiority in antibiotic stewardship 24 hours after randomization, defined as the proportion of patients receiving appropriate and proportionate antibiotic therapy, and non-inferiority in clinical pneumonia cure at 14 days, which was defined as the absence of death, septic shock, pneumonia relapse, or other signs of ongoing infection.

Secondary outcomes included 28-day mortality, incidence of septic shock, changes in organ dysfunction scores, and antibiotic hypersensitivity. Published in Intensive Care Medicine, the study found that the intervention group achieved superior antibiotic stewardship compared to the control group (76.5% vs. 55.9%; odds ratio, 2.57; 95% CI, 1.77-3.73). However, non-inferiority in clinical cure was not demonstrated, with the intervention group showing a lower clinical cure rate at 14 days (56.7%) compared to the control group (64.5%). Furthermore, there were no significant differences between the groups regarding progression of organ dysfunction, 28-day mortality, or antibiotic-associated adverse events, including septic shock, severe antibiotic hypersensitivity, and secondary pneumonia.

"We recommend that use of syndromic PCR to narrow antibiotic therapy should be cautious. We do not advise modification of current prescribing strategies until further data are available," stated the researchers.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.